SCHEMBL3586168

SCHEMBL3586168

Cc1ccc(S(=O)(=O)n2cc(F)cc2-c2coc([C@H]3CCCN(C(=O)c4ccc(F)cc4)C3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.47
CLPP Q16740 1/20 0.47
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
TSHR P16473 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPK1 P28482 2/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
MAP3K12 Q12852 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586170 1.00 GRM5 (0.47) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL27760147 0.85 GRM5 (0.42) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL3591832 0.83 BCL9 (0.42) RAB9AALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3584728 0.77 GRM5 (0.68) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL3584731 0.77 GRM5 (0.68) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL3585860 0.76 GRM5 (0.58) GRM5CLPPRAB9ATSHRMEN1
SCHEMBL3585856 0.76 GRM5 (0.58) GRM5CLPPRAB9ATSHRMEN1
SCHEMBL30794892 0.75 GRM5 (0.57) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL3585701 0.75 GRM5 (0.57) GRM5CLPPRAB9AALDH1A1LMNA
SCHEMBL3585711 0.75 GRM5 (0.57) GRM5CLPPRAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089386-B1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2012-08-08 EP disclosed
US-20100081690-A1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2010-04-01 US disclosed
EP-2089386-A2 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2009-08-19 EP disclosed
WO-2008056259-A2 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081690-A1 OXAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 GRM5 1/4885CLPP 4528/4885RAB9A 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.